A Phase I Study of Nimotuzumab With Nivolumab in Advanced Non-small Cell Lung Cancer and Head and Neck Squamous Cell Cancer
Asymptomatic troponin elevation was seen with this combination treatment. While there were no clinically significant adverse cardiac outcomes, further development was terminated due to the competitive landscape.
Authors
- Grace Kho Dy (ORCID: https://orcid.org/0000-0002-5061-0072)
- Patricia Lorenzo Luaces
- Adrienne Groman (ORCID: https://orcid.org/0000-0002-6837-2818)
- Tania Crombet (ORCID: https://orcid.org/0000-0002-2550-7292)
- Kalet León (ORCID: https://orcid.org/0000-0002-3709-7091)
- Orestes Santos Morales (ORCID: https://orcid.org/0000-0002-9468-8402)
- Rachel Frascati
- Syed Ather Hussain (ORCID: https://orcid.org/0009-0008-8909-9364)
- Amparo Macías
- Mary E. Reid
Institutions
- Roswell Park Comprehensive Cancer Center (US)
- Center of Molecular Immunology (Cuba) (CU)
Publication Details
- Journal
- Cureus
- Published
- 2025-12-09
- DOI
- https://doi.org/10.7759/cureus.98843
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00